Checkpoint Therapeutics Inc’s Post

Checkpoint Therapeutics today announced that the U.S. Food and Drug Administration has accepted for review Checkpoint’s resubmission of its Biologics License Application for cosibelimab. The resubmission has been accepted as a complete response to the FDA’s December 2023 complete response letter and the FDA has set a Prescription Drug User Fee Act goal date of December 28, 2024. Read the full release: https://lnkd.in/g_aJ5-N4

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

ir.checkpointtx.com

Rayone Wilson

Experienced Clinical Research Professional

3mo

This is great news! It’s been thrilling to see this journey from the first patients until now.

Mario West

Business|Product Development|Innovator| Social Entrepreneurship| CPG| 1 × Business Exit| Financial Literacy|Acquisitions| Marketing| Let's save the world 🌎

3mo

Great news! Looking forward to the FDA decision in December.

See more comments

To view or add a comment, sign in

Explore topics